Seetha Mahalaxmi Healthcare (SML), in a pioneering move last year, imported 256 GPUs to develop BharatGPT, an innovative generative AI platform, confirmed CEO Vishnu Vardhan.
Vardhan, also the co-founder of healthcare firm Vizzhy, the GPU buddy of BharatGPT, disclosed collaborations with two prominent hospital chains in India to construct VizzhyGPT, utilising hospital enterprise data. The CEO emphasised the strategic approach of charging hospitals for utilising the LLM.
Vardhan revealed plans for VizzhyGPT’s imminent launch and the acquisition of H100 GPUs to build foundational language models. Additionally, an arrangement with another company secured an extra 1,000 GPUs for developing a healthcare-specific LLM to serve both Indian and US markets.
“We have to depend on English for a lot of things,” explained Vardhan in an interview with AIM, that when it comes to science and healthcare, we are bound to look at it from an English lens, which becomes a huge barrier for research in India as 80% of the people are not proficient in the language. “People look at English just as another language, but they think in their native language.”
Most of the healthcare data is in English, but when it comes to talking to patients in India, the conversation between the doctor and the patient is mostly in local languages. He said that if most nurses at a hospital spoke Malayalam, it would become a problem for patients to interact with them and added that it is in cases like these that BharatGPT would come in handy.
VizzhyGPT, characterised as a multimodal model, aims to automate diverse hospital processes, encompassing clinical and non-clinical realms. With the capability to comprehend text, images, audio, and video files, VizzhyGPT promises to revolutionise the interpretation of medical imaging such as X-rays and magnetic resonance imaging (MRI) scans.
Vardhan, an esteemed orthopaedic and ballistic trauma surgeon, stressed the necessity for LLMs to possess clinical knowledge while deciphering complex medical data, such as endoscopy videos.
Harman, another significant player, unveiled HealthGPT, a private LLM, late last year. This advanced platform harnesses generative AI to enhance patient care, facilitate medical research, and streamline decision-making processes for healthcare professionals and institutions.
Meanwhile, HealthGPT, by Harman, addresses the challenge faced by healthcare professionals in staying updated within their medical specialties. Leveraging insights from publicly available clinical trial data, sourced primarily from clinicaltrials.gov, the platform aids in accelerating drug discovery and development processes.
Jai Ganesh, chief product officer of digital transformation solutions at Harman, elaborated on the extensive dataset drawn from various clinical trials globally, focusing initially on medical conditions like breast cancer, immune diseases, and heart diseases.
HealthGPT, tailored exclusively for doctors, clinicians, and regulators, is currently undergoing pilot testing with select customers and discussions with global pharmaceutical companies for further collaboration. The platform’s revenue model is structured around licensing fees, contingent upon usage and data volume, supplemented by subscription fees for continued access.
